Albireo Pharma HOME ABOUT ALBIREO Values The Teams PROGRAMMES PARTNERS INVESTORS CONTACT US Welcome Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) and liver disease areas. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities. Latest News 2014-04-11 Albireo’s Lead Compound in Cholestatic Liver Diseases, A4250, Protects Against Bile Acid-Mediated Cholestatic Liver Injury In Mice Read more 2014-03-06 Albireo has Initiated a Clinical Study Using A3384 in Patients with Bile Acid Malabsorption Read more Go to news archive Events DDW, Chicago, May 2014 About Albireo Programmes Partners Investors Contact Us Copyright © 2008 Albireo Accessibility Statement | Terms & Conditions | Site Map